AU2010294277B2 - 5- (3, 4-dichloro-phenyl) -N- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as HDL cholesterol raising agents - Google Patents

5- (3, 4-dichloro-phenyl) -N- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as HDL cholesterol raising agents Download PDF

Info

Publication number
AU2010294277B2
AU2010294277B2 AU2010294277A AU2010294277A AU2010294277B2 AU 2010294277 B2 AU2010294277 B2 AU 2010294277B2 AU 2010294277 A AU2010294277 A AU 2010294277A AU 2010294277 A AU2010294277 A AU 2010294277A AU 2010294277 B2 AU2010294277 B2 AU 2010294277B2
Authority
AU
Australia
Prior art keywords
compound
formula
prophylaxis
treatment
hdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010294277A
Other languages
English (en)
Other versions
AU2010294277A1 (en
Inventor
Stephan Roever
Matthew Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2010294277A1 publication Critical patent/AU2010294277A1/en
Application granted granted Critical
Publication of AU2010294277B2 publication Critical patent/AU2010294277B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010294277A 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -N- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as HDL cholesterol raising agents Active AU2010294277B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
EP09170097.1 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (2)

Publication Number Publication Date
AU2010294277A1 AU2010294277A1 (en) 2012-02-09
AU2010294277B2 true AU2010294277B2 (en) 2015-07-09

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010294277A Active AU2010294277B2 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -N- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as HDL cholesterol raising agents

Country Status (34)

Country Link
US (1) US8227491B2 (OSRAM)
EP (1) EP2475645B1 (OSRAM)
JP (1) JP5604520B2 (OSRAM)
KR (1) KR101382871B1 (OSRAM)
CN (1) CN102639506B (OSRAM)
AR (2) AR078352A1 (OSRAM)
AU (1) AU2010294277B2 (OSRAM)
BR (1) BR112012005511B8 (OSRAM)
CA (1) CA2771493C (OSRAM)
CL (1) CL2012000611A1 (OSRAM)
CO (1) CO6491033A2 (OSRAM)
CR (1) CR20120089A (OSRAM)
CY (1) CY1114377T1 (OSRAM)
DK (1) DK2475645T3 (OSRAM)
EC (1) ECSP12011723A (OSRAM)
ES (1) ES2423821T3 (OSRAM)
HR (1) HRP20130869T1 (OSRAM)
IL (1) IL217920A (OSRAM)
IN (1) IN2012DN00763A (OSRAM)
MA (1) MA33563B1 (OSRAM)
MX (1) MX2012002254A (OSRAM)
MY (1) MY161103A (OSRAM)
NZ (1) NZ597514A (OSRAM)
PE (1) PE20120863A1 (OSRAM)
PL (1) PL2475645T3 (OSRAM)
PT (1) PT2475645E (OSRAM)
RS (1) RS52987B (OSRAM)
RU (1) RU2541475C2 (OSRAM)
SG (1) SG179035A1 (OSRAM)
SI (1) SI2475645T1 (OSRAM)
TW (1) TWI412363B (OSRAM)
UA (1) UA107088C2 (OSRAM)
WO (1) WO2011029827A1 (OSRAM)
ZA (1) ZA201201599B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106054A1 (en) * 2005-04-06 2006-10-12 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
US7812028B2 (en) * 2006-10-04 2010-10-12 Hoffmann-La Roche Inc. 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106054A1 (en) * 2005-04-06 2006-10-12 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
US7812028B2 (en) * 2006-10-04 2010-10-12 Hoffmann-La Roche Inc. 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
AR078352A1 (es) 2011-11-02
PL2475645T3 (pl) 2013-12-31
IL217920A (en) 2015-11-30
IL217920A0 (en) 2012-03-29
US8227491B2 (en) 2012-07-24
TW201114427A (en) 2011-05-01
BR112012005511B1 (pt) 2021-03-02
PE20120863A1 (es) 2012-07-23
ZA201201599B (en) 2012-11-28
KR20120048040A (ko) 2012-05-14
NZ597514A (en) 2013-10-25
CN102639506A (zh) 2012-08-15
CR20120089A (es) 2012-03-22
IN2012DN00763A (OSRAM) 2015-06-26
CA2771493C (en) 2017-08-29
EP2475645A1 (en) 2012-07-18
HRP20130869T1 (hr) 2013-10-25
RU2541475C2 (ru) 2015-02-20
CO6491033A2 (es) 2012-07-31
MA33563B1 (fr) 2012-09-01
AU2010294277A1 (en) 2012-02-09
MX2012002254A (es) 2012-03-16
ES2423821T3 (es) 2013-09-24
RU2012113924A (ru) 2013-10-20
HK1172021A1 (en) 2013-04-12
WO2011029827A1 (en) 2011-03-17
DK2475645T3 (da) 2013-07-22
CA2771493A1 (en) 2011-03-17
AR114032A2 (es) 2020-07-15
MY161103A (en) 2017-04-14
TWI412363B (zh) 2013-10-21
BR112012005511B8 (pt) 2021-05-25
PT2475645E (pt) 2013-08-05
SG179035A1 (en) 2012-04-27
SI2475645T1 (sl) 2013-10-30
CL2012000611A1 (es) 2012-09-07
RS52987B (sr) 2014-02-28
CN102639506B (zh) 2014-09-03
ECSP12011723A (es) 2012-04-30
US20110065759A1 (en) 2011-03-17
CY1114377T1 (el) 2016-08-31
BR112012005511A2 (pt) 2016-04-19
JP5604520B2 (ja) 2014-10-08
EP2475645B1 (en) 2013-07-03
KR101382871B1 (ko) 2014-04-08
UA107088C2 (xx) 2014-11-25
JP2013504534A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
EP2475645B1 (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents
EP2651895B1 (en) Oxime compounds as hdl-cholesterol raising agents
EP2755952B1 (en) 5-cycloalkyl- or 5-heterocyclyl-nicotinamides
US8088920B2 (en) 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
KR101249668B1 (ko) Ｈｄｌ-콜레스테롤 상승제로서 2-트라이플루오로메틸니코틴아미드 유도체
EP2755950B1 (en) N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides
HK1172021B (en) 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof as hdl cholesterol raising agents
HK1193599B (en) N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides
HK1187912B (en) Oxime compounds as hdl-cholesterol raising agents
CN120943829A (zh) N-（2-（4-氰基噻唑烷-3-基）-2-氧乙基）喹啉-4-甲酰胺类化合物及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)